Back to top
more

CorMedix (CRMD)

(Delayed Data from NSDQ)

$11.64 USD

11.64
1,634,978

-0.03 (-0.26%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $11.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.

Zacks Equity Research

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

by Zacks Equity Research

Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.

Zacks Equity Research

FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

by Zacks Equity Research

Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.

Zacks Equity Research

Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat

by Zacks Equity Research

BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.

Zacks Equity Research

Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises

by Zacks Equity Research

AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.

Zacks Equity Research

UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y

by Zacks Equity Research

United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.

Zacks Equity Research

Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales

by Zacks Equity Research

ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.

Zacks Equity Research

Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?

by Zacks Equity Research

AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.

Zacks Equity Research

Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.

Zacks Equity Research

CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Company News for Jun 30, 2025

by Zacks Equity Research

Companies In The News Are: NKE, CNXC, CRMD, CORZ, CRWV.

Zacks Equity Research

Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?

by Zacks Equity Research

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

CI's Unit Unveils Offering to Expand Access to GLP-1 Medications

by Zacks Equity Research

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.

Zacks Equity Research

Is it a Good Idea to Invest in Immunocore Stock Right Now?

by Zacks Equity Research

IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.

Zacks Equity Research

EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint

by Zacks Equity Research

Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.

Zacks Equity Research

Factors That Make Centene Stock a Lucrative Pick Right Now

by Zacks Equity Research

CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock

by Zacks Equity Research

CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 29.41% and 1.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

by Zacks Equity Research

CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.

Zacks Equity Research

Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Best Momentum Stocks to Buy for November 8th

by Zacks Equity Research

CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.